Health Care [ 9/12 ] | Health Care Providers & Services [ 33/74 ]
NASDAQ | Common Stock
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States.
It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients.
The company's lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the potential treatment of autoimmune diseases and relapsed/refractory B-cell non-hodgkin's lymphoma.
It also develops ADI-270, an armored gamma delta CAR T cell product candidate to treat multiple CD70+ solid tumor and hematological malignancies indications, with renal cell carcinoma.
The company was founded in 2014 and is based in Boston, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 17, 25 | -0.32 Increased by +53.62% | -0.35 Increased by +9.86% |
| Nov 6, 24 | -0.34 Increased by +70.69% | -0.34 |
| Aug 8, 24 | -0.33 Increased by +56.01% | -0.36 Increased by +8.36% |
| May 14, 24 | -0.35 Increased by +51.39% | -0.39 Increased by +10.26% |
| Mar 19, 24 | -0.69 Increased by +4.17% | -0.69 |
| Nov 8, 23 | -1.16 Decreased by -118.87% | -0.74 Decreased by -56.76% |
| Aug 9, 23 | -0.75 Decreased by -33.93% | -0.68 Decreased by -10.29% |
| May 9, 23 | -0.72 Decreased by -820.00% | -0.69 Decreased by -4.35% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 0.00 Decreased by -100.00% | -28.73 M Increased by +2.58% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -30.48 M Increased by +38.90% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -29.90 M Increased by +7.72% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -28.02 M Increased by +5.44% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 12.89 M Increased by +151.60% | -29.49 M Decreased by -4.93% | Decreased by -228.70% Decreased by -303.37% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -49.88 M Decreased by -137.47% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -32.40 M Decreased by -44.86% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by -100.00% | -29.63 M Decreased by -741.55% | Decreased by N/A% Decreased by N/A% |